Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis
Reading Time: 7 minutes Zug, Switzerland: Full results from the phase III OLYMPIA 1 trial evaluating the efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis have been published in JAMA Dermatology, showing the trial met all primary and key secondary endpoints1
#24-409 Listing of Derivatives at NGM
Reading Time: < 1 minute Information about various derivatives that will be listed at NGM. For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market
FISKARS CORPORATION: ACQUISITION OF OWN SHARES 28.11.2024
Reading Time: < 1 minute Stock Exchange Release 28.11.2024 at 18:30 EET/EEST FISKARS CORPORATION: ACQUISITION OF OWN SHARES 28.11.2024 Date 28.11.2024 Exchange transaction Buy Share class FSKRS Amount 300 Average price/share 14.8196 EUR Highest price/share 14.8200 EUR Lowest price/share
STENOCARE Celebrates Denmark’s Permanent Legalisation of Medical Cannabis
Reading Time: 2 minutes STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO Today, the Danish parliament formally agreed on permanent legalisation of medical cannabis. This is fantastic news for both Danish patients and Stenocare, as it ensures continued access to and the sale of medical cannabis
NOTICE OF EXTRAORDINARY GENERAL MEETING IN PEPTONIC MEDICAL AB
Reading Time: 11 minutes N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in PEPTONIC medical AB, and in case of any discrepancies between the Swedish and the English translation, the Swedish text shall
SyntheticMR signs agreement to acquire Finnish Combinostics Oy
Reading Time: 6 minutes 28 November 2024, 22:55 CET SyntheticMR AB (“SyntheticMR” or the “Company”) has signed an agreement to acquire Finnish Combinostics Oy (“Combinostics”), through the acquisition of all shares in Combinostics, a leading medical technology and software solutions company focusing on cloud-based and AI-driven
NOTICE OF EXTRAORDINARY GENERAL MEETING IN PEPTONIC MEDICAL AB
Reading Time: 11 minutes N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in PEPTONIC medical AB, and in case of any discrepancies between the Swedish and the English translation, the Swedish text shall
Nordea Bank Abp: Repurchase of own shares on 28.11.2024
Reading Time: < 1 minute Nordea Bank AbpStock exchange release – Changes in company’s own shares28.11.2024 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 28.11.2024 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading venue (MIC Code) Number of shares Weighted average
Inside information, profit warning: Fondia Plc lowers its guidance on the outlook for 2024
Reading Time: < 1 minute Fondia Plc Company release, inside information 28.11.2024 at 10.10 p.m. EET Fondia lowers its outlook published on September 11, 2024, on net sales and operating profit for 2024 due to the continued difficult and uncertain market situation. The signs of
Fondia Plc: Share repurchase 28.11.2024
Reading Time: < 1 minute Fondia Plc Company release 28.11.2024 at 6.45 p.m. EET Fondia – Acquisition of own shares 28.11.2024 Fondia Plc First North Finland Date 28.11.2024 Exchange transactions Buy Share class FONDIA Amount, shares 269 Average price/share, EUR 5,660037